EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Circular Logic: Engineering Next‐Generation Circular RNA Therapeutics for Precision Oncology

Amr Ali Mohamed Abdelgawwad El-Sehrawy iD, Hamzeh J Al-Ameer, Jasur Rizaev, Ihsan K Jasim, Waleed Badrideen Mahmood, Laxmidhar Maharana, Divya Singhal, Neeraj Bainsal

Biotechnology and Bioengineering · 12.08.2026

DOI: 10.1002/bit.70344 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 12.08.2026. Verfasst von Amr Ali Mohamed Abdelgawwad El-Sehrawy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt. Die Arbeit nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The topology of RNA therapeutics is emerging as a critical design dimension in precision oncology. Unlike linear mRNA, circular RNA (circRNA) lacks free ends, conferring exceptional resistance to exonuclease degradation and enabling sustained protein expression for days to weeks. Beyond their use as engineered therapeutics, endogenous circRNAs exhibit cancer‐associated expression patterns and persistence in biofluids, supporting complementary roles in tumor biology and as candidate biomarkers for diagnosis and longitudinal disease monitoring. This review argues that circular topology should be viewed as an active pharmacologic variable, not merely a stability enhancement. We dissect recent advances in cap‐independent translation initiation, including IRES elements and m 6 A‐driven mechanisms, rolling‐circle translation for multi‐epitope vaccine design, and programmable stability circuits that integrate tumor‐microenvironment cues such as miRNA signatures. Delivery innovations are equally transformative: antibody‐guided lipid nanoparticles and engineered extracellular vesicles enable increasingly selective RNA delivery, while local depot formulations and organ‐selective systemic routes expand therapeutic reach. Safety considerations are re‐evaluated as double‐edged tools—innate immunogenicity can serve as a self‐adjuvant for cancer vaccines, whereas back‐splice‐junction neoantigens offer both vaccine opportunities and tolerance risks. Recent advances in scarless circularization, topology‐sensitive purification, dsRNA depletion, and lyophilized formulations have begun to address key manufacturing bottlenecks, although clinical‐scale recovery and process scalability remain insufficiently characterized. Key applications include circRNA cancer vaccines, transient CAR‐T/NK cell engineering, tumor‐suppressor replacement, and circRNA‐encoded bispecific T‐cell engagers. The field now requires real‐time pharmacokinetic tracking, reproducible and scalable manufacturing, validated liquid‐biopsy assays, and indication‐specific regulatory pathways to translate circRNA from bench to bedside.

Schlagwörter

Stichwörter der Autor:innen

RNA‐based cancer immunotherapycap‐independent translationcircular RNA therapeuticsnon‐viral RNA deliveryprecision oncology

Autor:innen und Institutionen

  • Internal medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt.
  • Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
  • Department of Public health and Healthcare management, Rector, Samarkand State Medical University, Samarkand, Uzbekistan.
  • Department of Pharmaceutical Sciences, College of Pharmacy, AL-Turath University, Baghdad, Iraq.
  • Department of Therapeutic Nutrition Techniques, College of Health and Medical Technologies, Alnoor University, Mosul, Iraq.
  • Department of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, India.

ORCID-Profile: Amr Ali Mohamed Abdelgawwad El-Sehrawy

Zitieren

APA

El-Sehrawy, A. A. M. A., Al-Ameer, H. J., Rizaev, J., Jasim, I. K., Mahmood, W. B., Maharana, L., Singhal, D., & Bainsal, N. (2026). Circular Logic: Engineering Next‐Generation Circular RNA Therapeutics for Precision Oncology. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70344

Vancouver

El-Sehrawy AAMA, Al-Ameer HJ, Rizaev J, Jasim IK, Mahmood WB, Maharana L, et al. Circular Logic: Engineering Next‐Generation Circular RNA Therapeutics for Precision Oncology. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70344

BibTeX
@article{ElSehrawy2026,
  author = {El-Sehrawy, Amr Ali Mohamed Abdelgawwad and Al-Ameer, Hamzeh J and Rizaev, Jasur and Jasim, Ihsan K and Mahmood, Waleed Badrideen and Maharana, Laxmidhar and Singhal, Divya and Bainsal, Neeraj},
  title = {Circular Logic: Engineering Next‐Generation Circular RNA Therapeutics for Precision Oncology},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70344}
}
Kostenlos starten →